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Abstract
Myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) are rare hematopoietic stem cell diseases
affecting children. Cytogenetics plays an important role in the diagnosis of these diseases. We report here the experience of
the Cytogenetic Subcommittee of the Brazilian Cooperative Group on Pediatric Myelodysplastic Syndromes (BCG-MDS-PED).
We analyzed 168 cytogenetic studies performed in 23 different cytogenetic centers; 84 of these studies were performed in
patients with confirmed MDS (primary MDS, secondary MDS, JMML, and acute myeloid leukemia/MDS+Down syndrome).
Clonal abnormalities were found in 36.9% of the MDS cases and cytogenetic studies were important for the detection of
constitutional diseases and for differential diagnosis with other myeloid neoplasms. These data show the importance of the
Cooperative Group for continuing education in order to avoid a late or wrong diagnosis.
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Introduction
The Brazilian Cooperative Group on Pediatric
Myelodysplastic Syndromes (BCG-MDS-PED) was
founded in January 1997 as a working group of
hematologists, pediatric hemato-oncologists, molecular
biologists, and other related professionals with the
following objectives: to provide support for diagnosis, to
offer treatment advice and educational instructions, to
perform studies and research, as well as to share
experiences about cases of pediatric (age ,18 years)
myelodysplastic syndromes (MDS). The BCG-MDS-PED
consists of eight distinct committees: morphology (cytol-
ogy, histopathology, and immunophenotyping); genetics
(cytogenetics, molecular biology, and clinical genetics);
epidemiology; secondary MDS; Down syndrome (DS);
bone marrow failures (congenital, acquired, and after
infections); myeloproliferative disorders and therapeutics,
in order to cover all aspects of MDS. We report here the
experience of the Cytogenetic Subcommittee.
Material and Methods
Since January 1985, 350 cases have been referred to
the BCG-MDS-PED, coming from 68 different public or
private centers, specialized or general, and located in 19
of the 26 states of Brazil. Some cases were included
retrospectively before the BCG-MDS-PED was founded.
The morphology committee reviewed peripheral blood/
bone marrow smears and biopsies and classified
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the cases according to the WHO-Pediatric-Hasle’s
classification (1).
Karyotypes were obtained at local centers when
available and reviewed by the Cytogenetic Committee
(EDRPV, MLC, SRCT) or at one of the four university
centers in Sa˜o Paulo. Karyotyping was performed in bone
marrow samples using the Giemsa banding technique
and chromosomal abnormalities were described accord-
ing to the International System for Human Cytogenetic
Nomenclature (ISCN 2009) (2). Chromosome fragility was
induced with the diepoxybutane (DEB) test in suspected
cases of Fanconi anemia. Some cytogenetic centers
performed FISH studies for monosomy 7 in cases with
less than 20 metaphases analyzed and BCR/ABL1
rearrangement for a differential diagnosis between juve-
nile myelomonocytic leukemia (JMML) and chronic
myeloid leukemia (CML).
After the review, 156 cases were confirmed as
childhood MDS (de novo or secondary), JMML, or acute
myeloid leukemia/MDS with DS (AML/MDS+DS), 129
cases did not meet the diagnostic criteria and 65 cases
had no definitive diagnosis (in revision, inconclusive or
insufficient sample).
For the 82 MDS patients with cytogenetic studies and
evolution, we calculated overall survival and survival
according to the cytogenetic profile (normal, chromosome
7 abnormality and other abnormalities). The same
evaluation was performed for the 65 patients with well-
known therapy, censoring the time of allogeneic hemato-
poietic stem cell transplantation (HSCT) (performed in 13
of them). Statistical analysis was performed using the
Kaplan-Meier product limit estimation (survival curves)
and log rank test to compare groups. The data were
analyzed using the SPSS software.
Results
Of the 350 cases included in the BCG-MDS-PED
database, 168 had been submitted to conventional
cytogenetic studies (bone marrow karyotype) and 76
were reviewed by the committee. At least 23 cytogenetic
centers located in 7 different Brazilian States, most of
them in Sa˜o Paulo (capital and interior of the state) were
responsible for the study. Figure 1 shows the origin of all
350 patients and the distribution of the cytogenetic
centers.
Although the number of cases with karyotype studies
was small, we observed an increase in the percentage of
cases with cytogenetics according to the period of
diagnosis: 8.3% (1985 to 1990), 29.4% (1991-1995),
49.3% (1996-2000), 56.6% (2001-2005), and 50% (2005-
2010). The abnormal cytogenetic studies according to
final diagnosis are shown in Table 1.
Childhood MDS was confirmed in 84 cases who had
conclusive cytogenetic studies (5 cases showed no
metaphases), including 11 with refractory cytopenia
(RC), 48 with refractory anemia with excess of blasts
(RAEB) or RAEB in transformation (RAEB/T), 4 with
unclassified MDS, 11 with JMML, 7 with AML/MDS+DS,
and 3 with secondary MDS. Results were abnormal in
45.2% of cases (38/84). Clonal abnormalities were found
in 31 (36.9%) cases, 4 of them also with constitutional
trisomy 21. Seven cases (8.3%) showed only constitu-
tional abnormalities, including 4 cases with trisomy 21, 1
with balanced translocation t(8;9) and 2 with a positive
DEB test.
Monosomy 7/deletion 7q was the most frequent clonal
abnormality, found in 11 cases (13.9%), followed by
trisomy 8 (4.7%) and 21; 2 or more abnormalities were
seen in 5.9% of cases. Clonal abnormalities were more
frequent in AML/MDS+DS (42.8%), RAEB/T (37.5%),
JMML (36.4%), and secondary MDS (33.3%) than in RC
(27.2%). In AML/MDS+DS, trisomy 8 and an extra copy of
an isoderivative of chromosome 21 were found as clonal
abnormalities in 2 cases and 1 case, respectively.
The median overall survival was 31 months for the
MDS group (n = 82 patients), 122 months for the
subgroup with chromosome 7 abnormality (n = 11
patients), 35 months for the subgroup with abnormal
karyotype but no chromosome 7 abnormality (n = 19
patients), and 29 months for normal karyotype (n = 52
patients). No significant differences were detected in the
survival of these 3 groups (P = 0.4; Figure 2A). The
median survival obtained by censoring the time of
allogeneic HSCT was 29 months for the MDS group (n
= 65 patients), a time not reached by the subgroup with
chromosome 7 abnormality (n = 8 patients), 36 months
for the subgroup with abnormal karyotype but no
chromosome 7 abnormality (n = 17 patients), and 28
months for patients with a normal karyotype (n = 40).
Again, no significant differences were detected in the
survival of these 3 groups (P = 0.4; Figure 2B).
Of 129 cases reviewed by the Morphology Committee
who did not show childhood MDS, 53 had cytogenetic
studies (but 4 cases showed no metaphases), 15 (30.6%)
showed karyotype abnormalities, 1 of them characterized
as constitutional in one boy with aplastic anemia who
showed a balanced translocation involving the long arm of
chromosome 3 and short arm of chromosome 5. Eight
cases were diagnosed as AML, 3 with -7/7q- abnormal-
ities, 2 with t(8;21), 2 with trisomy 8, one with del(11q23),
and another with t(15;17). Karyotyping confirmed 3 cases
of CML with Philadelphia chromosome, and 1 case of
primary myelofibrosis with additional material on chromo-
some 22.
An interesting t(1;5)(q23;q33) translocation was
detected in an 11-month-old girl with anemia, thrombocy-
topenia, leukocytosis with monocytosis, and marked
eosinophilia. She was first diagnosed by our Committee
as having unclassified MDS or MDS/myeloproliferative
disorder. In cooperation with the Dana-Farber Cancer
Institute and Harvard Medical School, the t(1;5)(q23;q33)
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translocation was cloned, showing the fusion of the
platelet-derived growth factor receptor beta (PDGFRB)
gene to the myomegalin gene. After imatinib therapy, the
patient achieved a long- term hematological remission, and
is still alive, more than 10 years after the diagnosis (3). This
disease is now called myeloid and lymphoid neoplasm with
eosinophilia and abnormalities in the PDGFRB gene,
according to the WHO 2008 classification (4).
Discussion
Childhood MDS and JMML are a group of clonal
hematopoietic disorders occurring in 1.2 and 1.8 children
per million per year, respectively (1). Cytogenetics plays
an important role in the diagnosis of these rare diseases.
The incidence of clonal cytogenetic abnormalities in
childhood MDS ranges from 50 to 80% and monosomy
7/deletion 7q was the most frequent abnormality
described in Europe (5,6) and in the USA (7). Trisomy
21 (inherited or acquired) was also common, but trisomy 8
and 5q deletions (often described in adult MDS) were
detected in only a few cases (7). The European Working
Group of Myelodysplastic Syndrome in Childhood
(EOWG-MDS group) demonstrated that 36% of JMML
cases showed clonal abnormalities, and monosomy 7 was
detected in 26% of the cases (8). The role of cytogenetics
in the prognosis of childhood MDS was published in few
studies. In 1995, Passmore et al. (9) proposed a score
that included platelet counts and fetal hemoglobin; but it
was not validated by others (7). The French group
Figure 1. Map of Brazil showing the distribution of 350 patients included in the Brazilian Cooperative Group on Pediatric
Myelodysplastic Syndromes (BCG-MDS-PED) database (1987-2007). Most of the cytogenetic centers are concentrated in the Brazilian
states of the South and Southeast.
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Table 1. Cytogenetic abnormalities in 52 patients with confirmed myelodysplastic syndromes and with other diagnoses.
Diagnosis Karyotype studies Complementary cytogenetic tests
RC 40,46,XY,del(7)(q32)[6]/46,XY[7]
RC 45,XY,-7[20]
RC 46,XX,dup(1)(p1.1)[11]
RAEB 45,XX, -7[7],46,XX[1]
RAEB 45,XY,-7[16]/46,XY[4]
RAEB 45,XY,-7[5]/46,XY[2] FISH positive for monosomy 7
RAEB 45,XY,-7[7]/46,XY[7] FISH positive for monosomy 7
RAEB 45,XX,-7[10]/46,XX[5] FISH positive for monosomy 7
RAEB Absence of metaphases FISH positive for monosomy 7
RAEB 46,XX,del(12)(p?)[6]/47,XX,+9[3]/46,XX[5]
RAEB 46,XY,? t(9;13)(p22;q12),t(11;12)(q13;p13)[23]/46,XY[7]
RAEB 46,XY,del(18)((q?),del (22)(q?)[10]
RAEB 46,XY,del(3)(p25?)[7]/46,XY[12]
RAEB 46,XY,del(9)(p13),add(9)(q34),del(12)(p13)[cp8]/46,XY[11]
RAEB 46,XY,t(3;5)(q24;q33)[20]
RAEB 47, XY,+8[20]/46,XY[1]
RAEB 47,XY,+21[5]
RAEB 47,XY,+mar[4]/46,XY[1]
RAEB 48,XXX,+13[18]/46,XX[2]
RAEB 46,XX[20] positive DEB test
RAEB 46,XX[20] positive DEB test
RAEB 46,XY,t(8;9)(q22;p22)c[22]
RAEB/T 45,XY,-7[10]
RAEB/T 47,XY,+8[10]/46,XY[10]
JMML 45,XY,-7[20]
JMML 45,XY,-7[17]
JMML 46,XY,add(9)(p?)[4]/46,XY[8]
JMML 47,XY,+21[20]
U-MDS 47,XY,+mar[2]/46,XY[8]
Secondary MDS 46,XX,del(21)(q?)[2]/46,XX[9]
MDS/AML+DS 48,XY,der(21;21)(q10;q10)c,+der(21;21)(q10;q10),+21[3]/
47,XY,der(21;21)(q10;q10)c,+21[14]
MDS/AML+DS 48,XX,+8,+21c[6]/47,XX,+21c[2]
MDS/AML+DS 46,XY,add(7)(p22),-17,+21c[20]
MDS/AML+DS 48,XX,+8,+21c[4]/47,XX,+21c[2]
MDS/AML+DS 47,XX,+21c[20]
MDS/AML+DS 47,XX+21c [20]
MDS/AML+DS 47,XX+21c[20]
MDS/AML+DS 47,XY+21c[20]
AML 45,X,-Y,del(7)(q32?),t(8;21)(q22;q22)[20]
AML 46,XY,add(3)(q28),t(8;21)(q22;q22),del(9)(q?21)[12]/46,XY[1]
AML 46,XY, t(15;17)(q22;q21)[20]
AML 46,XX,del(11)(q23)[5]/46,XX[21]
AML 45,XY,-7[15]
AML 45,XY,-7[11]
AML 46,XX,del(7)(q22)[12]/46,XX[2]
AML 47,XX,+8[30]
Aplastic anemia 46,XY,t(3;5)(q25;p15)c[20]
CML 46,XX, t(9;22)(q34.1;q11.2)[20]
CML 46,XX, t(9;22)(q34.1;q11.2)[20]
Continued on next page
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studying 44 children with MDS showed that monosomy 7
was associated with intermediate prognosis (Groupe
Franc¸ais de Cytoge´ne´tique He´matologique, 1997) (5).
Monosomy 7 was not associated with unfavorable prog-
nosis in JMML by the EOWG-MDS group (8). In 2010, the
EOWG-MDS group studied prospectively 192 children with
advanced MDS and identified that the presence of a
structurally complex karyotype was the strongest indepen-
dent prognostic marker predicting poor outcome, with only
14% of a 2-year survival in this group (10).
Before the founding of the BCG-MDS-PED in 1997,
there were almost no studies describing the incidence,
clinical evolution or transformation of childhood MDS in
Brazil. At first, the idea of this cooperative group was to
review cases of the entire country and give diagnostic
support (morphology, genetics, etc.). In parallel, a
teaching initiative was designed in order to disseminate
the concepts and tools for a correct and quick MDS
diagnosis in children. The results of these initiatives are
shown here. More than 350 cases were reviewed, 156 of
which were correctly classified as MDS according to the
WHO pediatric approach. Morphology, histology, and
cytogenetic analysis were reviewed by a central commit-
tee and the evaluation was confirmed. As expected, most
of these cases (113/157) were de novo MDS and a few
were secondary. Also, AML and JMML were well defined,
as well as DS cases.
Clonal abnormalities were found in 36.9% cases and
only 13.9% of them had monosomy 7. Unfortunately, the
small number and heterogeneity of cases and the loss to
follow-up in some of them could not allow us to define the
role of cytogenetic subgroups in prognosis. However, more
than this, cytogenetics was very important in defining
diseases as AML with t(8;21), CML and even myeloid and
lymphoid diseases with PDGFRB rearrangement that have
a better survival and require specific therapies.
Brazil is a huge country, with a territorial extent of
8,511,996.3 km2, with more than 5500 cities and 180
million inhabitants, most of them concentrated in the
Southwest region, which is also the most economically
Table 1. Continued.
Diagnosis Karyotype studies Complementary cytogenetic tests
CML 46,XX,del(4),t(9;22)(q34.1;q11.2)[20] FISH positive for BCR/ABL1 rearrangement
Myelofibrosis 46,XX,add(22)(q13)[4]/46,XX[7]
MLN PDGFRB 46,XX,t(1;5)(q23;q33)[24] FISH positive for PDGFRB
rearrangement
AML = acute myeloid leukemia; CML = chronic myeloid leukemia; DEB = positive diepoxybutane test; FISH = fluorescence in situ
hybridization; JMML = juvenile myelomonocytic leukemia; MDS/AML+DS = myelodysplastic syndrome/AML associated with Down
syndrome; MLN PDGFRB = myeloid and lymphoid neoplasia with eosinophilia and abnormalities in the PDGFRB gene; RC =
refractory cytopenia; RAEB = refractory anemia with excess of blasts; RAEB/T = RAEB in transformation; U-MDS = unclassified
MDS.
Figure 2. Kaplan-Meier overall survival curves for patients with myelodysplastic syndromes according to the cytogenetic profile and to
chromosome 7 abnormalities vs other abnormalities vs normal. A, Overall survival. B, Survival with censoring of the time of allogeneic
hematopoietic stem cell transplantation.
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rich and with an estimated adequate number of
physicians/inhabitants. As shown, most of the MDS
cases came from Sa˜o Paulo State (Southeast). In
Northern or Central states of Brazil not even a single
MDS case was detected, a fact that raises concern
about the possibility that cases may still be misdiag-
nosed in these regions. This indicates the need for
continuing education and awareness of pediatricians
regarding the different aspects of disease manifestation
in order to avoid a late or wrong diagnosis. Very
interesting lessons can be drawn from this collaborative
study: the joint effort brought benefits to patients,
relatives and physicians as well as some social,
scientific, and economical profits.
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